Company Overview - Arrowhead Pharmaceuticals is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapeutics targeting serious diseases, particularly liver disorders and cardiometabolic conditions [8][9] - The company has a robust clinical pipeline that includes drug candidates such as ARO-AAT, ARO-APOC3, and JNJ-3989, and generates revenue through licensing agreements, research collaborations, and milestone payments from pharmaceutical partners [8][9] - As of the most recent financial data, Arrowhead Pharmaceuticals has 609 employees, a total revenue of $829.45 million, and a net income of -$1.63 million for the trailing twelve months (TTM) [5] Recent Developments - On December 17, 2025, CEO Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals for approximately $5.44 million, which aligns with his historical trading activity [1][2][7] - The sale occurred during a period of significant stock performance, with a total return of 249.37% over the prior year, and the stock closing at $64.80 on the transaction date [2][12] - The timing of the sale suggests it was part of a tax-planning strategy related to performance awards that vested in December [4][11] Market Context - The stock price surged following the FDA approval of Arrowhead's first medicine, plozasiran (marketed as Redemplo), for treating familial chylomicronemia syndrome, reaching a 52-week high of $76.76 on January 6 [12] - The current elevated price-to-sales ratio indicates that while it may be a good time for shareholders to sell, waiting for a price drop before reinvesting could be a more strategic approach [13] Competitive Edge - Arrowhead Pharmaceuticals' competitive advantage lies in its proprietary RNAi delivery technologies, which enable the treatment of previously untreatable diseases [10]

Company Overview - Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a biopharmaceutical company focused on developing medicines that treat intractable diseases through RNA interference (RNAi) therapeutics [1] - The company competes with other biotech firms in the RNAi space, including Alnylam Pharmaceuticals and Ionis Pharmaceuticals [1] Insider Trading Activity - On January 5, 2026, Hamilton James C, the Chief Medical Officer, sold 4,625 shares at $61.24 each, retaining 207,497 shares post-sale [2] - Mauro Ferrari, a Director, sold 7,530 shares at an average price of $70, totaling $527,100, and reduced his ownership by 9.83% [3] - Ferrari previously sold 8,750 shares at $56.39 each, totaling $493,412.50 [3] Stock Performance - Arrowhead's stock opened at $66.39, reflecting a 1.3% decrease, and is currently priced at $63.88, down 5.77% or $3.91 [4] - The stock has fluctuated between $60.62 and $68 during the trading day, with a yearly high of $72.36 and a low of $9.57 [4] - The company's market cap is approximately $8.83 billion [4] Trading Volume and Momentum - The trading volume for ARWR today is 2,692,400 shares [5] - The stock's 50-day moving average is $53.54, indicating recent upward momentum despite recent insider sales [5][6] - Arrowhead remains a significant player in the biopharmaceutical industry, focusing on RNAi therapeutics [6]

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being developed as potential treatments for obesity. Preliminary results with Arrowhead's promising new approach to treating obesity and metabolic diseases showed meaningful reductions in multiple key measures, including visceral fat, total fat, and liver. ...

About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision ...

Core Viewpoint - Alnylam Pharmaceuticals is highlighted as a promising biotech stock with significant growth potential, particularly due to its innovative RNA interference (RNAi) therapies and recent product approvals [2][5][13]. Company Overview - Alnylam Pharmaceuticals was co-founded in 2002 by MIT professor Phillip Sharp, who also co-founded Biogen in 1978 [4]. - The company focuses on RNA interference (RNAi) as a novel therapeutic approach, which has gained recognition with a Nobel Prize in 2006 [5]. Financial Performance - An investment of $10,000 in Alnylam at its IPO would be worth approximately $787,000 today, indicating strong historical performance [6]. - The company's market capitalization is currently $61 billion, with a gross margin of 83.90% [9]. Product Pipeline and Growth - Alnylam received FDA approval for its RNAi therapy Onpattro in 2018, targeting a rare genetic disease, and has since launched another therapy, Amvuttra, which is expected to become a blockbuster drug [7][9]. - Sales of Amvuttra increased by 162% year-over-year in Q3 2025, showcasing strong market demand [10]. - The company is evaluating nucresiran in phase 3 clinical studies for additional ATTR indications [10]. Collaborations and Licensing - Alnylam has outlicensed its RNAi therapies, including Leqvio to Novartis and Qfitia to Sanofi, which helps mitigate risk while still generating revenue [9][14]. - The company is collaborating with Regeneron on cemdisiran and with Roche on zilebisiran, expanding its therapeutic reach [11][12]. Future Outlook - Alnylam's forward price-to-earnings ratio is 53.5, reflecting high growth expectations already priced into the stock [13]. - The company’s RNAi platform has the potential to address a wide range of diseases beyond its current focus, suggesting long-term growth opportunities [15]. - While the investment outlook remains uncertain, the company is expected to continue generating significant returns for patient investors [16].

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to complement the Zacks Rank, helping investors identify stocks likely to outperform the market in the short term [2] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum characteristics, with A being the highest score [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - Concentrates on a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - Targets stocks with upward or downward price trends, utilizing recent price changes and earnings estimate revisions to identify buying opportunities [5] VGM Score - Combines Value, Growth, and Momentum Scores to provide a comprehensive assessment of stocks, aiding in the selection of the most attractive investment opportunities [6] Zacks Rank Integration - The Zacks Rank uses earnings estimate revisions to identify stocks with the highest potential returns, with 1 (Strong Buy) stocks historically achieving an average annual return of +23.64% since 1988 [7][8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment success [9] Company Spotlight: Alnylam Pharmaceuticals - Alnylam Pharmaceuticals is a biopharmaceutical company specializing in RNA interference therapeutics, with a pipeline targeting genetic, cardio-metabolic, and hepatic infectious diseases [11] - The company has received multiple FDA approvals for its products, including Onpattro, Givlaari, Oxlumo, and Amvuttra, addressing various medical conditions [11] - Currently, Alnylam has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a strong Momentum Style Score of A, indicating potential for upward movement [12][13]

Core Insights - The FDA has granted fast track designation to Sanofi's SAR446268, a one-time AAV gene therapy for treating non-congenital myotonic dystrophy type 1 (DM1), aimed at expediting its development and review process [1][7] Group 1: Product Development - SAR446268 utilizes a vectorized RNA interference (RNAi) approach to silence DMPK expression, potentially addressing key symptoms of DM1 such as muscle weakness and myotonia [2][3] - The therapy is currently undergoing a first-in-human, phase 1-2 study to assess its safety, tolerability, and efficacy, with the first patient expected to be enrolled in late 2025 [3] Group 2: Disease Overview - Myotonic dystrophy type 1 is a rare genetic disorder affecting approximately 1 in 2,300 people globally, characterized by progressive muscle weakness and various systemic effects [4] - There are currently no approved treatments for DM1, highlighting the unmet medical need that SAR446268 aims to address [4][7] Group 3: Company Profile - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [5]

Core Viewpoint - Silexion Therapeutics Corp. has announced a public offering of 1,500,000 ordinary shares and accompanying warrants at a price of $4.00 per share, aiming to raise approximately $6.0 million to advance its pre-clinical studies and for general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes 1,500,000 ordinary shares, series A warrants, and series B warrants, all priced at $4.00 per share [1]. - Series A warrants will have an exercise price of $4.00, exercisable immediately, and will expire five years from issuance [1]. - Series B warrants will also have an exercise price of $4.00, exercisable immediately, but will expire twelve months from issuance [1]. - The offering is expected to close on or about September 12, 2025, pending customary closing conditions [1]. Group 2: Financial Aspects - The gross proceeds from the offering are expected to be $6.0 million before deducting fees and expenses [2]. - The net proceeds will be utilized to advance pre-clinical studies and for general corporate purposes [2]. Group 3: Company Background - Silexion Therapeutics is focused on developing RNA interference therapies for KRAS-driven cancers, particularly targeting solid tumors with mutated KRAS oncogenes [5]. - The company has conducted a Phase 2a clinical trial for its first-generation product, showing a positive trend compared to chemotherapy alone [5]. - Silexion is committed to advancing therapeutic options in oncology, specifically for locally advanced pancreatic cancer [5].

Industry Overview - The biopharmaceutical industry is experiencing challenges due to ongoing tariffs and drug pricing pressures from the Trump administration, leading to a 5.7% decline in the combined market capitalisation of the top 20 global biopharmaceutical companies, from $3.92 trillion on March 31, 2025, to $3.70 trillion on June 30, 2025 [1] Company Performances - Alnylam achieved the largest market capitalisation growth of 21.8%, reaching $42.5 billion, driven by strong sales of its RNA interference therapeutic Amvuttra, which saw a 59% year-on-year increase in global sales to $310 million in Q1 2025 [2] - Novartis reported a 7.7% increase in market capitalisation in Q2 2025, bolstered by strong sales of blockbuster drugs such as Entresto, Cosentyx, Kesimpta, and Kisqali, along with the acquisition of Regulus Therapeutics for $1.7 billion, enhancing its renal disease portfolio [3] - Bristol Myers Squibb experienced the largest decline in market capitalisation at 22.9% due to mixed Q1 2025 financial results and negative trial outcomes, particularly the failure of its Phase III ARISE trial for Cobenfy [4] - Regeneron and Sanofi saw market capitalisation declines of 18.7% and 13.8%, respectively, following the failure of their partnered drug itepekimab in the Phase III AERIFY-2 trial, which aimed to reduce exacerbations of chronic obstructive pulmonary disease [5]

As filed with the Securities and Exchange Commission on September 5, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER (Primary Standard Industrial Classification Code Number) Cayman Islands 8731 N/A (I.R.S. Employer Identification Number) THE SECURITIES ACT OF 1933 Silexion Therapeutics Corp (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 12 Abba Hill ...